# Inclisiran

## Leqvio 284mg/1.5mL pre-filled syringe

| TAH Drug Code      | [ILEQ](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ILEQ)                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Atherosclerotic cardiovascular disease, secondary prevention Familial hypercholesterolemia, heterozygous Familial hypercholesterolemia, homozygous                                                                                                                                                            |
| Dosing             | SUBQ: Initial: 284 mg as a single injection, again at 3 months, and then every 6 months thereafter.                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity (eg, angioedema) to inclisiran or any component of the formulation.                                                                                                                                                                                                                          |
| Adverse Effects    | 1% to 10%: Immunologic: Antibody development (5%) Local: Injection-site reaction (8%; including erythema at injection site, pain at injection site, rash at injection site) Neuromuscular & skeletal: Arthralgia (5%) Respiratory: Bronchitis (4%) Postmarketing: Hypersensitivity: Hypersensitivity reaction |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                       |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/inclisiran-drug-information)                                                                                                                                                                                                                                     |

